Issue 3/2013
Content (15 Articles)
Letter to the Editor
Secondary Cytoreduction Versus Chemotherapy Alone in the Treatment of Patients with Recurrent Ovarian Cancer: Is a Randomized Trial Worthwhile?
Paolo Sammartino, Daniele Biacchi, Marialuisa Framarino
Letter to the Editor
In Reply: Response to Sammartino et al.
Philipp Harter, Florian Heitz, Andreas du Bois
Invited Commentary
Provider Impact on Survival Outcomes in the Management of Malignant Disease
Maurie Markman
Invited Commentary
Clinical Trials of Neoadjuvant Chemotherapy for Ovarian Cancer: What Do We Gain After an EORTC Trial and After Two Additional Ongoing Trials Are Completed?
Keiichi Fujiwara, Akira Kurosaki, Kosei Hasegawa
Invited Commentary
Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?
Susana Banerjee, Martin Gore
Hot Topic
The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion
Michael Bradshaw, Aaron Mansfield, Tobias Peikert
Genitourinary Cancers (E Jonasch, Section Editor)
Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
Sausan Abouharb, Paul G. Corn
Genitourinary Cancers (E Jonasch, Section Editor)
Novel Immunotherapies in GU Malignancies
Alexandra Drakaki, David F. McDermott
Genitourinary Cancers (E Jonasch, Section Editor)
Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?
Yago Nieto
Genitourinary Cancers (E Jonasch, Section Editor)
New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer
Erin E. Ezzell, Kuang S. Chang, Benjamin J. George
Palliative Medicine (A Jatoi, Section Editor)
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem
Viswanath Reddy Belum, Alyssa Fischer, Jennifer Nam Choi, Mario E. Lacouture
Palliative Medicine (A Jatoi, Section Editor)
Clearing the Air: A Review of Our Current Understanding of “Chemo Fog”
Erin O’Farrell, Joyce MacKenzie, Barbara Collins
Palliative Medicine (A Jatoi, Section Editor)
Benefit and Harms of New Anti-Cancer Drugs
Francisco E. Vera-Badillo, Mustafa Al-Mubarak, Arnoud J. Templeton, Eitan Amir
Palliative Medicine (A Jatoi, Section Editor)
Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
Morgan Trammel, Mary Roederer, Jai Patel, Howard McLeod